Full Press Release Details
Prior to joining the interdepartmental program of critical care at the University of Toronto, he served as a senior intensive care physician at a leading Israeli hospital - the Tel Aviv Sourasky Medical Center (Ichilov), where he initiated its institutional extracorporeal membrane oxygenation (ECMO) program. A director of the Medical ICU at Sourasky Medical Center since 2020 and is also Treasurer of the Israeli ECMO Society since 2019.
BioSphera Ltd .: Specialized in pre - clinical research Prof Eli Gabbay, MD, FRACP Res p i r atory Ad visor Dr. Yigal Kasif, MD ECMO Advisor Dr. Avraham Abutbul, MD ICU Respiratory Advisor Dr. Orit Cohen Jacob, MDV Clinical & Research Advisor Scientific Advisory Board - cont. Dr. Dekel Stavi, MD I n tens i vist Ad visor Has considerable experience in leadership and Extracorporeal Life Support programs, cardiology aspects of Intensive Care Unit ("ICU") patients and treating hemato - oncology patients in ICUs.
Current research: Chronic Obstructive Pulmonary Diseases, &prevention of sepsis related organ dysfunction with Allocetra. Veterinary surgeon & expert in laboratory animal science, Israeli Prime Minister's Office, Chairwoman of the National Animal Experimentation Ethics Committee, Founder of GLP/GMP companies: SeruMed GMP Ltd .: Production of anti - venom serum .
Cambridge University, UCLA, Hebrew University of Jerusalem, Cardiac surgery clinical fellowship in UCLA and research fellowship at Cedars Sinai Medical Center. Senior physician at the Medical Intensive Care unit and at the Pulmonology Institute at the Hadassah Medical Center. Lecturer at the Hebrew University Faculty of Medicine & Hadassah Medical School.
Chairman of Research at UND, Director of the WA Lung Transplant Program, Sub - training at Freeman Hospital in Newcastle upon Tyne, Stanford University, Palo Alto & the Alfred Hospital, Melbourne. Cardiac Surgeon & Director of ECMO Israel, Adult Cardiac Surgery, Heart Transplants, Assist Devices & ECMO, Intensive Care Treatment, Sheba Medical Center at Sheba Hospital.
Serial entrepreneur & investor. Multi - industry experience in growing companies from concept to market penetration and sales. Cardiologist, ICU Physician & Cardiology Researcher, Senior hyperbaric & diving physician. Sheba Medical Center, Israel Naval Medical Institute, Technion Institute of Technology, Meir Medical Center, Tel Aviv University P r o f .
A Grade 2C recommendation is a very weak recommendation; other alternatives may be equally reasonable. 2. Brown 3rd CA, Walls RM. The decision to intubate. In: The Walls Manual of Emergency Airway Management, 5th ed, Lippincott Williams & Wilkins, Philadelphia 2018. p.3. 3. https:// www.elso.org/Portals/0/ELSO%20Guidelines%20General%20All%20ECLS%20Version%201_4.pdf (Accessed on July 23, 2018).
Our scientific advisory board members, who are experts in their fields, were integrally involved in or viewed the studies at real - time. 32.13 mmHg 26.91 mmHg Partial Pressure of carbon dioxide A R T O f f * ART On* 84.96% 94.76% Oxygen Saturation levels ART O f f * ART O n* 49.3 mmHg 65.08 mmHg Partial Pressure of Oxygen A R T O f f * ART On* SaO PaO pCO (P<0.0001) (P<0.0001) (P<0.0001) No significant change * Average results Copyright 2018 - 2021 Inspira Technologies OXY B.H.N.
Our scientific advisory board members, who are experts in their fields, were integrally involved in or viewed the studies at real - time. ART's Respiratory Support System Potential Benefits Reduced costs associated with MV c om p li ca tions Increased patient throughput Better respiratory care in ward setting Reduction of patient load in ICU Reduced staffing - No need for perfusionists No need for surgical access team The patient's perspective Immediate oxygen saturation elevation Decreased work of breathing: x Improving compliance to HFNC x Improving compliance to pronation Patient can communicate their symptoms and needs No need for induced coma Avoiding all forms of complications associated with MV Copyright 2018 - 2021 Inspira Technologies OXY B.H.N.
A novel therapy Revolutionary early extracorporeal respiratory support system ,intended to rebalance saturation and carbon dioxide levels in patients with acute respiratory failure, while they are awake and breathing App r o a c h i n g bot h IC U an d non - I C U markets Cost - effective, designed for deployment in and outside the ICU, in urban and rural hospitals Copyright 2018 - 2021 Inspira Technologies OXY B.H.N.
ID: 5129035 2. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease - Second Edition. Sheffield, European Respiratory Society, 2017. The respiratory care market size is estimated to reach approximately $29.86 Bn by 2025 E st a b lis he d nee d ~20 million patients annually admitted to ICUs, requiring acute respiratory care , being intubated and placed on mechanical ventilation * Trademarks are the property of their respective owners.
M V r equ i r e s i n tru si v e i n tub a t i o n , c om a i nduct io n , a n d c a n b e v e r y t r a u m a t i c f o r p a t i e n t s : Potential Risks & Complications Ventilator - induced lung injury (VILI) Ventilator - associated pneumonia (VAP) Ventilator - induced diaphragmatic dysfunction Pneumothorax & tracheomalacia Oxygen toxicity of the lung Delirium Muscular atrophy High Cost of Treatment Long hospital stays Increased complication rate Patient re - admissions Requires weaning process Extended rehabilitation period Mechanical Ventilation Has Significant Downsides 3 Copyright 2018 - 2021 Inspira Technologies OXY B.H.N.
Frontiers in pharmacology MINI REVIEW published: 09 May 2019. doi: 10.3389/fphar.2019.00482 3. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital - acquired and Ventilator - associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61 - e111.
If the Company does update one or more forward - looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward - looking statements . 1. Am J Respir Crit Care Med Vol. 196, P3 - 4, 2017. ATS Patient Education Series 2017 American Thoracic Society 2. Diling Wu et al.
Forward - looking statements speak only as of the date the statements are made . The Company assumes no obligation to update forward - looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward - looking information except to the extent required by applicable securities laws .
For a more detailed description of the risks and uncertainties affecting the Company, the reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the risks detailed in the Company's preliminary prospectus dated June [ 28 ], 2021 , filed with the SEC as a part of the Company's Registration Statement on Form F - 1 (File No . 333 - 253920 ), and documents incorporated by reference therein .
However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed or indicated by the forward - looking statements . Forward - looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward - looking statements .
The presentation also contains estimates with respect to the Company's health economics model . Forward - looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain . Such expectations, beliefs and projections are expressed in good faith .
Words such as "expects," "intends," "plans," "believes," "seeks," "estimates," and similar expressions or variations of such words are intended to identify forward - looking statements . For example, the Company is using forward - looking statements when it discusses its vision, the potential of its product, its strategy, market potential for its product, its paradigm, commercialization of its product, the potential to use its product together with mechanical ventilation, reimbursement strategy for its product, regulatory approval process of its product candidates, the benefits and use of its product candidates " intended patient population, lines of therapy and market milestones 2021 - 2023 to FLS and its future growth .